Table 2.

Molecular response (IWG-MRT/ELN criteria)^a

	Ruxolitinib-randomized (n = 102)	Ruxolitinib crossover (n = 94)	BAT (n = 85)
CMR, n (%)	2 (2.0)	1 (1.1)	0
Median time to CMR (weeks)	143.4	123.0	N/A
PMR, n (%)	33 (32.4)	20 (21.3)	1 (1.2)
Median time to PMR (weeks)	112.0	91.9	32.0

BAT best available therapy, CMR complete molecular response, IWG-MRT/ELN International Working Group–Myeloproliferative Neoplasms Research and Treatment/European LeukemiaNet, N/A not applicable, PMR partial molecular response

^aAmong patients with a positive JAK2 p.V617F mutation at baseline and ≥1 postbaseline assessment of allele burden